Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | FLT3 | P36888 | 8/20 | 0.60 |
| ▸ | RAF1 | P04049 | 7/20 | 0.58 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.58 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.58 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.58 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.57 |
| ▸ | KDR | P35968 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23170027 | 0.89 | MAPK14 (0.54) | MAPK14MEN1NPC1RAB9AKMT2A | |
| SCHEMBL442236 | 0.84 | RAB9A (0.65) | MEN1NPC1RAB9AKMT2AKDR | |
| SCHEMBL1257268 | 0.82 | FLT3 (0.54) | NPC1RAB9AFLT3RAF1KDR | |
| SCHEMBL13234418 | 0.80 | MAPK14 (0.78) | MAPK14MEN1NPC1RAB9AKMT2A | |
| SCHEMBL2943933 | 0.80 | MAPK14 (0.78) | MAPK14MEN1NPC1RAB9AKMT2A | |
| SCHEMBL13234435 | 0.80 | MAPK14 (0.78) | MAPK14MEN1NPC1RAB9AKMT2A | |
| SCHEMBL13234666 | 0.80 | MAPK14 (0.78) | MAPK14MEN1NPC1RAB9AKMT2A | |
| SCHEMBL13234447 | 0.80 | MAPK14 (0.69) | MAPK14MEN1NPC1RAB9AKMT2A | |
| SCHEMBL13234430 | 0.79 | MAPK14 (0.76) | MAPK14MEN1NPC1RAB9AKMT2A | |
| SCHEMBL13264366 | 0.79 | MAPK14 (0.76) | MAPK14MEN1NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4448521-A1 | REVERSIBLE MACROCYCLIC KINASE INHIBITORS | Crossfire Oncology Holding B.V. (NL) | 2024-10-23 | — | — | EP | disclosed |
| WO-2023110936-A1 | REVERSIBLE MACROCYCLIC KINASE INHIBITORS | NETHERLANDS TRANSLATIONAL RESEARCH CENTER HOLDING B.V (NL) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023110936-A1 | REVERSIBLE MACROCYCLIC KINASE INHIBITORS | NETHERLANDS TRANSLATIONAL RESEARCH CENTER HOLDING B.V (NL) | 2023-06-22 | — | — | WO | disclosed |
| US-20130035326-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-02-07 | — | — | US | disclosed |
| EP-2467137-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2012-06-27 | — | — | EP | disclosed |
| WO-2011022473-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035326-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | FLT3, CSF3R, CSF1R | MAPK14 1534/4885MEN1 1373/4885NPC1 1964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.